Abstract:
BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 to December 2013, the clinical data of patients who experienced local-regional recurrence after curative esophagectomy were collected and analyzed to determine local-regional recurrence patterns and to evaluate whether a proposed T-shaped PORT CTV could cover regions of local-regional failure. RESULTS:A total of 108 patients were eligible for this study. All patients experienced postoperative recurrence of lower TESCC. The time to local-regional failure varied from one to 52 months (average 13.4 ± 11.0). Among the 108 patients, 127 recurrence sites were detected as the first recurrence event: 37 cases in the bilateral supraclavicular region, 56 in the upper mediastinum, 14 in the middle mediastinum, 15 in the upper abdominal lymph nodes, and five cases of anastomotic recurrence. The proposed PORT CTV could successfully cover 89 (82.4%) out of the 108 recurrences and 84.2% of the sites (107/127) of recurrence in our sample. CONCLUSION:Local-regional recurrence of lower TESCC is mainly distributed in the supraclavicular, upper-middle mediastinum, anastomotic stoma, and upper abdominal lymph node regions. The proposed T-shaped PORT CTV field could cover over 80% of local-regional failure in our sample; therefore, we suggest that PORT should focus on this area.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Liu J,Cai X,Liu Q,Li H,Cheng Y,Fu Xdoi
10.1111/1759-7714.12499subject
Has Abstractpub_date
2017-11-01 00:00:00pages
630-633issue
6eissn
1759-7706issn
1759-7714journal_volume
8pub_type
杂志文章相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12925
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13163
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12504
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13308
更新日期:2020-03-01 00:00:00
abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12013
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Few studies have been conducted on the relationship between chronic periodontitis and postoperative pneumonia (POP) in patients with lung and esophageal cancer. Furthermore, it remains controversial as to whether improving the periodontal condition of patients with lung and esophageal cancer before surgery r...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13828
更新日期:2021-01-24 00:00:00
abstract::Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12263
更新日期:2016-03-01 00:00:00
abstract::Most tumor cells show different metabolic pathways than normal cells. Even under the conditions of sufficient oxygen, they produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, which is known as aerobic glycolysis or the Warburg effect. Lung cancer is a malignant tumor with o...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/1759-7714.12148
更新日期:2015-01-01 00:00:00
abstract::Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13785
更新日期:2021-01-12 00:00:00
abstract:BACKGROUND:We explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. METHODS:Data from 293 patients with lung adenocarcinoma were classifi...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12419
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...
journal_title:Thoracic cancer
pub_type: 临床试验,杂志文章
doi:10.1111/1759-7714.12966
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:The purpose of this study was to investigate the risk factors of postoperative complications and reliable prognostic factors of long-term survival in HIV-infected patients with non-small cell lung cancer (NSCLC). METHODS:HIV-infected patients with NSCLC who underwent surgical treatment were retrospectively ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13519
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12824
更新日期:2018-12-01 00:00:00
abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13372
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13256
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12818
更新日期:2018-09-01 00:00:00
abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13175
更新日期:2019-10-01 00:00:00
abstract:BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13080
更新日期:2019-07-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12557
更新日期:2018-01-01 00:00:00
abstract::Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12484
更新日期:2017-11-01 00:00:00
abstract:BACKGROUND:This study aims to evaluate the incidence and characteristics of chyle leakage after curative oncologic esophagectomy, and the effectiveness of thoracic duct ligation. METHODS:This is a retrospective cohort study using the medical records of 1514 patients who underwent curative esophagectomy for esophageal ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12105
更新日期:2014-09-01 00:00:00
abstract::Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12277
更新日期:2015-11-01 00:00:00
abstract:BACKGROUND: The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2012.00152.x
更新日期:2013-05-01 00:00:00
abstract:BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12895
更新日期:2019-01-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12646
更新日期:2018-06-01 00:00:00
abstract:BACKGROUND:The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). METHODS:IPF with lung cancer from tertiary hospitals consisted of 1685 patients who had been diagnosed between 2003 and 2007. We reviewed their medical record...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/j.1759-7714.2011.00107.x
更新日期:2012-05-01 00:00:00
abstract::The extravasation of cytotoxic agents into subcutaneous tissue is a serious complication of chemotherapy. Unfortunately, if such extravasation occurs into the pleural space, limited data is available to guide appropriate management. We present the first report in the literature of video-assisted thoracoscopy combined ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12430
更新日期:2017-07-01 00:00:00
abstract::Selected patients with non small-cell lung cancer (NSCLC) with mediastinal lymph node involvement may have a survival benefit from surgical resection, particularly if mediastinal nodal down-staging occurs after induction therapy and complete resection is achieved with lobectomy. Accurate re-staging of the mediastinum ...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/j.1759-7714.2011.00097.x
更新日期:2012-05-01 00:00:00
abstract::A squamous cell lung cancer patient was treated with pneumonectomy. A recurrent lung cancer (adenocarcinoma) was found 45 months later and successfully biopsied and treated with microwave ablation. After 18 months of follow up, no evidence of tumor recurrence was observed. ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12244
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12846
更新日期:2018-11-01 00:00:00